secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspira Women's Health Inc. (AWHL)
CIK:        0000926617
Form:       8-K
Filed at:   2025-06-11T23:59:59+00:00
Accession:  0001641172-25-014701
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspira Women's Health says ARPA-H terminated $10M ENDOinform contract after receiving $3.5M
--------------------------------------------------------------------------------

- ARPA-H terminated $10M contract for ENDOinform test on June 9, 2025, citing unmet Milestone 3 specs.
- Aspira had received $2M and $1.5M milestone payments (Nov 2024, Mar 2025) totaling $3.5M.
- Company disputes termination, claims it met all Milestone 3 requirements and was progressing on Milestone 4.
- CEO says R&D team will continue ENDOinform development targeting 2026 completion with shareholder and partner support.
- Contract termination may accelerate development pace due to reduced administrative burden.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/926617/000164117225014701/0001641172-25-014701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/926617/000164117225014701/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-014701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer